Eli Lilly and Company (NYSE:LLY) Shares Sold by Fidelity D & D Bancorp Inc.

Fidelity D & D Bancorp Inc. decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 12.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 345 shares of the company’s stock after selling 50 shares during the quarter. Fidelity D & D Bancorp Inc.’s holdings in Eli Lilly and Company were worth $268,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. Trexquant Investment LP acquired a new stake in Eli Lilly and Company during the third quarter valued at approximately $3,874,000. Morningstar Investment Services LLC raised its stake in Eli Lilly and Company by 112.8% during the third quarter. Morningstar Investment Services LLC now owns 1,741 shares of the company’s stock valued at $948,000 after buying an additional 923 shares in the last quarter. Ancora Advisors LLC raised its stake in Eli Lilly and Company by 2.9% during the third quarter. Ancora Advisors LLC now owns 6,935 shares of the company’s stock valued at $3,725,000 after buying an additional 198 shares in the last quarter. Gotham Asset Management LLC raised its stake in Eli Lilly and Company by 111.3% during the third quarter. Gotham Asset Management LLC now owns 7,386 shares of the company’s stock valued at $3,967,000 after buying an additional 3,891 shares in the last quarter. Finally, Kinloch Capital LLC raised its stake in Eli Lilly and Company by 25.8% during the third quarter. Kinloch Capital LLC now owns 717 shares of the company’s stock valued at $385,000 after buying an additional 147 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the company. JPMorgan Chase & Co. upped their price objective on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. Argus upped their target price on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a report on Tuesday, May 14th. Truist Financial reaffirmed a “buy” rating and set a $1,000.00 target price (up from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Citigroup upped their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Finally, Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $812.72.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the sale, the chief accounting officer now owns 7,130 shares in the company, valued at approximately $5,842,821.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, major shareholder Lilly Endowment Inc sold 17,229 shares of the stock in a transaction on Monday, June 24th. The stock was sold at an average price of $902.38, for a total value of $15,547,105.02. Following the completion of the sale, the insider now owns 97,556,910 shares in the company, valued at $88,033,404,445.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. In the last 90 days, insiders sold 789,704 shares of company stock worth $672,385,964. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $905.38 on Friday. The stock has a fifty day moving average price of $814.40 and a two-hundred day moving average price of $739.86. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The firm has a market cap of $860.48 billion, a P/E ratio of 133.34, a PEG ratio of 1.97 and a beta of 0.36. Eli Lilly and Company has a 1 year low of $434.34 and a 1 year high of $915.54.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm’s quarterly revenue was up 26.0% on a year-over-year basis. During the same period last year, the company posted $1.62 EPS. Research analysts forecast that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.57%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.